<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04763486</url>
  </required_header>
  <id_info>
    <org_study_id>0189-19-MMC</org_study_id>
    <nct_id>NCT04763486</nct_id>
  </id_info>
  <brief_title>Prophylactic Antibiotic After Perineal Tear</brief_title>
  <acronym>PATPET</acronym>
  <official_title>Prophylactic Antibiotic Treatment for Perineal Tear After Delivery: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meir Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current World Health Organization guidelines recommend routine antibiotic prophylaxis for&#xD;
      women with perineal tear 3rd and 4th degree but not for 2nd degree because of insufficient&#xD;
      evidence of effectiveness. The investigators aimed to investigate whether antibiotic&#xD;
      prophylaxis prevented maternal infection after the first and second perineal tear after&#xD;
      vaginal birth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PATPET trial is a randomized, controlled trial done at tertiary hospital obstetric units&#xD;
      in Israel. Women who had first and second-degree tear (or after episiotomy) after delivery at&#xD;
      37 weeks or greater gestation, with no indication for ongoing prescription of antibiotics in&#xD;
      the post-partum period and no contraindications to prophylactic Cefamezin (cefazolin), were&#xD;
      randomly assigned (1:1) to receive a single intravenous dose of prophylactic antibiotic or&#xD;
      not.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>parturition</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with a fever after delivery</measure>
    <time_frame>6 weeks of delivery</time_frame>
    <description>Maternal fever above 38 C (Celsius)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Way of delivery</measure>
    <time_frame>6 weeks of delivery</time_frame>
    <description>Type of delivery- vacuum-assisted delivery vs. vaginally</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Puerperal Infection</condition>
  <arm_group>
    <arm_group_label>Prophylactic antibiotic treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will be given Cefamezin antibiotic within 6 hours of delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Will not get antibiotic prophylactics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin (Cefamezin)</intervention_name>
    <description>Cefamezin 2 gr within 6 hour of delivery</description>
    <arm_group_label>Prophylactic antibiotic treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18-45&#xD;
&#xD;
          -  perineal tear 2nd and 1st degree( episiotomy)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  3rd and 4 th degree perineal tear&#xD;
&#xD;
          -  antibiotic indication during delivery&#xD;
&#xD;
          -  cesarian section delivery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Delivery</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gil Shechter, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meir Medical Center , Tel Aviv University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yair Daykan, Dr</last_name>
    <phone>+972542198231</phone>
    <email>yair.dykan@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba,</city>
        <zip>11125</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 29, 2019</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>February 20, 2021</last_update_submitted>
  <last_update_submitted_qc>February 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Meir Medical Center</investigator_affiliation>
    <investigator_full_name>Yair Daykan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Puerperal Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefazolin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Yes</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

